PET Imaging of mGLuR5 With Drug Challenge

What is the purpose of this trial?

This study is designed to look at that involvement of a process in the brain called the glutamate system in depression. Participants will undergo a screening session, up to two fMRI scans, and up to three PET scans, as well as cognitive testing at each scan session. For one of the PET scans, a drug (either ketamine or n-acetyl cysteine) will be administered.

Hypothesis 1: The investigators hypothesize administration of ketamine or n-acetylcysteine (NAC) will lead to a decrease in mGluR5.

Hypothesis 2: The investigators hypothesize an improvement in memory and attentional skills after drug challenge.

Hypothesis 3: The investigators hypothesize an increase in mGluR5 availability and change in MRI measures post drug challenge as compared to baseline, signifying synaptogenesis.

Hypothesis 4: We expect there should not be a significant difference in reduction in mGluR5 availability due to differences in ABP688 radiotracer infusion.


Participation Guidelines

Ages: 18 - 65 years

Gender: Both


National Institutes of Health

Start Date: 06/27/2012

End Date: 11/15/2023

Last Updated: 03/06/2018

Study HIC#: 1111009365

Get Involved

For more information about this study, contact:
Nicole DellaGioia
+1 203-737-6884
nicole.dellagioia@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image